Purpose or Objective:
This study analyzed whether shortterm death of patients with peripheral stage I NSCLC can be predicted reliably to select a sub-group of patients, which will not have a benefit from SBRT and which can be referred to wait and see.
Material and Methods: 802 patients with early stage NSCLC treated with SBRT in 5 institutes for whom information on overall survival within the first six months after treatment was available were included in this analysis. The probability of dying within six months after treatment was modeled by multivariate logistic regression; this interval was chosen because death of early stage NSCLC is a rare event within six months after diagnosis. Model fitting was performed using the LASSO method which simultaneously serves to select the features most closely related to the outcome. The performance of the model that would be achieved on an independent dataset was estimated using double 10-fold cross validation (CV). Because with CV the estimation of test performance depends somewhat on the splitting of the data sets, double 10-fold CV was repeated 100 times, resulting in 1000 models from which the variance in the performance measure could be obtained. The variables age, gender, ECOG status, operability, FEV1 and Charlson comorbidity index (CCI) where considered for model building.
Results: Using different variable combinations for model building resulted in different sample sizes and model performances (Table 1) . Common among all models was the identification of the CCI as the most frequently selected and thus most important variable predicting six-months death, with increasing values predicting higher probability of death. Gender was consistently the second-most frequently selected variable. Regressing on the individual components of the CCI with the LASSO method showed that presence of a second solid tumor was the most important predictor, followed by various forms of heart disease (Figure 1 ). Replacing the CCI by these individual components in model building confirmed the strong relation between the presence of a second tumor and early death, but led to a worse model performance than with the full CCI (Table 1) . Overall the accuracy of all models predicting six-months death was poor with maximum AUC=0.62.
Conclusion:
General patient characteristics together with comorbidity data, especially the history of a previous malignancy, can predict early death, however, prediction accuracy is insufficient to select patients to wait and see instead of offering SBRT as a curative treatment.
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Purpose or Objective: NRG/RTOG 0813 is a phase I/II study designed to determine the maximal tolerated dose (MTD) and efficacy of SBRT for NSCLC with centrally located tumors. We hereby report the primary endpoint of the phase I portion of the study.
Material and Methods:
Medically inoperable pts with biopsy proven, PET staged T1-2 (<5cm)N0M0 NSCLC and centrally located tumors (within or touching the zone of the proximal bronchial tree or adjacent to mediastinal or pericardial pleura) were successively accrued onto a dose-escalating 5 fraction SBRT schedule ranging from 10-12 Gy/fraction delivered over 1.5-2 weeks. Dose-limiting toxicity (DLT) was defined as any grade 3 or worse toxicity (per CTCAE v.4) occurring within first year, possibly, probably, or definitely related to treatment from a pre-specified list of cardiac, esophageal, respiratory or neurological toxicities. Any potential DLT within the initial year post-SBRT could have led to dose reduction for subsequent patients accrued, using TITE-CRM (time-to-event continual reassessment method) statistical design. MTD was defined as SBRT dose associated with a 20% probability of DLT.
Results: 120 pts were accrued Feb 2009 to Sept 2013 from 43 participating centers. Numbers (n) accrued into each cohort, n eligible for analysis (20 pts were excluded as they did not receive protocol treatment (12) or were ineligible (8)), and n evaluable for DLT analyses (11 not evaluable, 10 of whom died in the first year without a DLT) are shown in the table. Pts were elderly (median age 72), slightly more females (57%), majority had performance status 0-1 (84%). Most cancers were T1 (65%) and squamous cell (45%). Median follow up was 26.6 months. There were 5 events that met the definition of DLTs; Table details the protocol pre-specified DLTs and the worst treatment-related AEs (ie occurring at any time). MTD is 12.0 Gy/fr; Bayesian-based probability of DLT on this arm was 7.2% (95% CI 2.8 -14.4%). The grade 5 AEs occurred at a mean 13 mo postSBRT (range 5.5-14mo).
Conclusion:
The rates of toxicity pre-specified as DLT were relatively low. The highest dose level allowed by the protocol was reached, and associated with 7.2% rate of DLT. This phase I/II trial of SBRT provides data to inform patients of the potential toxicities with a 5 fraction SBRT schedule for centrally located NSCLC, but data on efficacy are still awaited.
OC-0137
Tumour size but not location determines survival and control of lung stereotactic body radiotherapy M. Roach 1 Siteman Cancer Center, Radiation Oncology, Saint Louis, USA 1 , S. Rehman 1 , T. DeWees 1 , J. Bradley 1 , C. Robinson 1 Purpose or Objective: Patients with early stage non-small lung carcinoma (NSCLC) located centrally within the thorax present a therapeutic challenge with stereotactic body radiation therapy (SBRT). We compared outcomes of early stage NSCLC located in central and peripheral locations.
Material and Methods:
A total of 472 patients with early stage NSCLC were identified from a prospective IRB-approved thoracic SBRT registry. Tumors were classified as central if they were within 2 cm of the proximal bronchial tree or immediately adjacent to the mediastinal or pericardial pleura. Peripheral tumors were treated to 54 Gy in 3 fractions, and central tumors to 50 or 55 Gy in 5 fractions. Patients were reviewed for overall survival (OS) calculated from completion of therapy and local failure (LF). The logrank test and Cox regression were used to identify factors predictive of OS and LF.
Results: 127 patients had central tumors and 345 had peripheral tumors. Median follow-up was 30 months for living patients. For the entire cohort at 2 years, OS was 57% and LF was 10%. OS at 2 years was 50% for patients with central tumors and 60% for those with peripheral tumors (p=0.11). LF at 2 years was 19% for central lesions and 8% for peripheral lesions (p=0.08). On multivariate analysis, increasing tumor size (HR 1.21 per cm, 95% CI: 1.10-1.33, p<0.0001), increasing age-adjusted Charlson comorbidity score (HR 1.15 per point, 95% CI: 1.09-1.20, p<0.0001), and worse KPS (HR 10.1 per 10% loss, 95% CI: 10.1-10.2, p=0.0003), but not location predicted for worse OS. Only increasing tumor size (HR 1.37/cm, 95% CI: 1.06-1.78, p=0.02) predicted for LF on multivariate analysis.
Conclusion:
The use of five SBRT fractions of 10-11 Gy for central early stage NSCLC results in similar outcomes as peripheral early stage NSCLC treated in three SBRT fractions of 18 Gy. Larger tumors result in worse outcomes suggesting the need for additional treatment strategies.
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